Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Johnston, Stephen; Harbeck, Nadia; Hegg, Roberto; M, Toi; Martín, Miguel; Min Shao, Zhi; Yuan Zhang, Qing; Luis Martinez Rodriguez, Jorge; Campone, Mario; Hamilton, Erika; K Sohn, J; Guarneri, Valentina; Okada, Morihito; M Boyle, F; Neven, Patrick; Cortés, Javier; Huober, Jens; Wardley, Andrew; M. Tolaney, Sara; Çiçin, İrfan; C. Smith, Ian; Frenzel, Martin; Headley, Desirée; Wei, Ran; San Antonio, Belén; Hulstijn, Maarten; Cox, Joanne; O'Shaughnessy, J; Rastogi, Priya

doi:10.1200/jco.20.02514

Public

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Published in Journal of Clinical Oncology • Sep 20, 2020

Authors:

Stephen Johnston

Nadia Harbeck

Roberto Hegg

Abstract

PURPOSE: Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the fir...

Subject

Medicine

Oncology

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!